About this trial
An active lifestyle after a cancer diagnosis can reduce the side effects of treatment and improve quality of life, mental health, and survival. Recent evidence in the literature confirms its benefits across various types and stages of cancer. However, the majority of cancer patients do not reach the recommended levels of physical activity due to physical, psychological, and logistical barriers. It is essential that healthcare professionals provide motivational support and address individual barriers to physical activity through the active involvement of patients, thus promoting the adoption and maintenance of an active lifestyle. To achieve this, personalization of physical activity programs is crucial. For this reason, the MOvement \& REhabilitation clinic was established in 2022, where a dedicated physiotherapist provides personalized consultations and educational support to promote physical activity among cancer patients.
This study aims to evaluate the trend over time in the amount of physical activity among cancer patients attending the "MOvement and REhabilitation" (MO.RE) clinic. The study also seeks to assess patient engagement, the amount of resources used to help patients maintain an active lifestyle, and any barriers to physical activity.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of cancer
Age over 18 years
Signed informed consent
Patients for whom a physical exercise program can be proposed
Disqualifiers
Patients for whom the physiatric assessment identifies a need for individual rehabilitative treatment
Significant language barrier
Neuropsychological, psychiatric, or cognitive deficits, or clinical conditions that prevent participation in an independent physical activity program
Trial population
Adult cancer survivors (≥18 years) accessing the MO.RE. clinic. Eligible participants have a history of cancer, can provide informed consent, and are suitable for a structured physical activity program. Patients requiring individualized rehabilitation, with significant language barriers, or with neurocognitive, psychiatric, or clinical conditions that prevent safe participation in independent physical activity are excluded.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Weekly aerobic activity
Collection of the minutes of aerobic physical activity performed in the previous 7 days
Secondary outcomes
Overall physical activity level
The overall physical activity level will be calculated using the International Physical Activity Questionnaire (IPAQ-SF), both in categorical form (low activity levels, moderate activity levels, high activity levels) and continuos form (MET minutes per week)
Patient engagement
The level of patient engagement will be categorical, with the following stages: pre-contemplation, contemplation, determination, action.
Number of session completed
The session completed and the monitoring activities will be expressed as a number per patients
Exercise-related adverse events
Number and type of adverse events (e.g., falls, fractures, pain exacerbation requiring medication) assessed and attributed to exercise by study clinician.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.